Self‐interaction of soluble and surface‐bound β2‐glycoprotein I and its enhancement by lupus anticoagulants

[1]  K. Mertens,et al.  Mechanisms of Disease: antiphospholipid antibodies—from clinical association to pathologic mechanism , 2008, Nature Clinical Practice Rheumatology.

[2]  P. D. de Groot,et al.  Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. , 2007, Blood.

[3]  S. Rahgozar,et al.  Current concepts on the pathogenesis of the antiphospholipid syndrome. , 2007, Blood.

[4]  Kazuko Kobayashi,et al.  Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. , 2006, Progress in lipid research.

[5]  P. D. de Groot,et al.  Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. , 2006, Blood.

[6]  C. Esmon,et al.  Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies. , 2005, Blood.

[7]  A. Schroit,et al.  Recruitment of beta-2-glycoprotein 1 to cell surfaces in extrinsic and intrinsic apoptosis , 2005, Apoptosis.

[8]  Y. Ikeda,et al.  Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. , 2005, Blood.

[9]  R. Derksen,et al.  Pathogenic anti- β 2 -glycoprotein I antibodies recognize domain I of β 2 -glycoprotein I only after a conformational change , 2005 .

[10]  P. D. de Groot,et al.  beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome. , 2004, Clinical immunology.

[11]  M. Hammel,et al.  Solution Structure of Human and Bovine β2-Glycoprotein I Revealed by Small-angle X-ray Scattering , 2002 .

[12]  Manfred Kriechbaum,et al.  Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering. , 2002, Journal of molecular biology.

[13]  R. Schwarzenbacher,et al.  Mechanism of the interaction of beta(2)-glycoprotein I with negatively charged phospholipid membranes. , 2001, Biochemistry.

[14]  I. Nishii,et al.  Identification of the phospholipid-binding site of human beta(2)-glycoprotein I domain V by heteronuclear magnetic resonance. , 2000, Journal of molecular biology.

[15]  Y. T. Sun,et al.  Membrane-induced conformational change in human apolipoprotein H. , 2000, The Biochemical journal.

[16]  J. Vermylen,et al.  Beta-2-glycoprotein I Dependent Lupus Anticoagulants Form Stable Bivalent Antibody Beta-2-Glycoprotein I Complexes on Phospholipid Surfaces , 1998, Thrombosis and Haemostasis.

[17]  H. Takeya.  Anti-β2-glycoprotein I (β2GPI) Monoclonal Antibodies with Lupus Anticoagulant-like Activity Enhance the β2GPI Binding to Phospholipids , 1997 .

[18]  T. Koike,et al.  Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. , 1997, The Journal of clinical investigation.

[19]  G. Willems,et al.  Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. , 1996, Biochemistry.

[20]  M. Igarashi,et al.  Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. , 1996, Blood.

[21]  J. Nishioka,et al.  β2-Glycoprotein I Modulates the Anticoagulant Activity of Activated Protein C on the Phospholipid Surface , 1996, Thrombosis and Haemostasis.

[22]  D. Borchman,et al.  Interactions and molecular structure of cardiolipin and β2‐glycoprotein 1 (β2‐GP1) , 1995 .

[23]  T. Yasuda,et al.  Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface , 1994, The Journal of experimental medicine.

[24]  H. Brewer,et al.  beta 2-Glycoprotein I. Molecular properties of an unusual apolipoprotein, apolipoprotein H. , 1983, The Journal of biological chemistry.